All In Biotech

Drug Trial Radar · NCT06175351

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

A Randomized, Double-Blind, Placebo-Controlled Phase Ib/IIa Clinical Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 20, 2026Latest source record: May 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jul 6, 2023

Primary completion

Sep 30, 2025

Study completion Sep 30, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the pharmacokinetic characteristics, safety, tolerability, and preliminary efficacy of 9MW1911 in combination with standard of care COPD maintenance therapy in patients with moderate to severe COPD.

Conditions

  • Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • 9MW1911Drug

    Participants will receive IV 9MW1911 every 4 weeks.

  • PlaceboDrug

    Participants will receive IV placebo every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic characteristics.Time frame: 36 weeks
  2. Pharmacokinetic characteristics.Time frame: 36 weeks
  3. Pharmacokinetic characteristics.Time frame: 36 weeks
  4. Pharmacokinetic characteristics.Time frame: 36 weeks
  5. Pharmacokinetic characteristics.Time frame: 36 weeks
  6. Pharmacokinetic characteristics.Time frame: 36 weeks
  7. Safety and tolerabilityTime frame: 36 weeks

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Baogang Hospital (No 3 Hospital Affiliated to Medical College of Inner Mongolia)

    Baotou, China

  • China-Japan Friendship Hospital

    Beijing, China

  • Peking University Shougang Hospital

    Beijing, China

  • The First Hospital of Changsha

    Changsha, China

  • The second xiangya hospital of central south university

    Changsha, China

  • Chengdu Fifth People's Hospital

    Chengdu, China

  • Chongqing Red Cross Hospital (People's Hospital of Jiangbei District)

    Chongqing, China

  • Fu Yang People's Hospital

    Fuyang, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China

  • The Third Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China

  • The Second Hospital, University of South China

    Hengyang, China

  • The Third People's Hospital of Huizhou

    Huizhou, China

  • Jiangmen Central Hospital

    Jiangmen, China

  • Liaocheng People's Hospital

    Liaocheng, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • Pingxiang People's Hospital

    Pingxiang, China

  • The First Affiliated Hospital of Qiqihar Medical University

    Qiqihar, China

  • Tongji Hospital of Tongji University

    Shanghai, China

  • Shengjing Hospital of China Medical University

    Shenyang, China

  • Suzhou Municipal Hospital

    Suzhou, China

  • The First Hospital of Shanxi Medical University

    Taiyuan, China

  • Taizhou Hospital of Zhejiang Province

    Taizhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.